O. El-Rasheidy, Shahira F El-Fedawy, H. Tomoum, Mona B El-Zeany
{"title":"儿童和青少年癫痫患者的抗磷脂抗体","authors":"O. El-Rasheidy, Shahira F El-Fedawy, H. Tomoum, Mona B El-Zeany","doi":"10.4314/EJPAI.V2I1","DOIUrl":null,"url":null,"abstract":"Background: Some immunologic mechanisms of epilepsy are cited in literature. The possibility that epilepsy might be associated with the production of autoantibodies has not been sufficiently addressed. Objective: This study investigates the prevalence of some antiphospholipid antibodies in pediatric primary epilepsy in relation to the type of seizures, the duration of the disease and the antiepileptic drugs received. Methods: The study included 37 patients in the pediatric age groups with epilepsy (30 with idiopathic epilepsy and 7 with cryptogenic epilepsy); 10 of them were newly diagnosed in comparison to ten healthy children. The patients were subjected to clinical, laboratory and radiologic evaluation to verify the diagnosis and to exclude thrombotic or autoimmune collagen disorders. Anticardiolipin IgG and IgM and anti-β 2 -glycoprotein I IgG and IgM antibodies were measured in all subjects using the ELISA technique. Results: Forty percent of the patients were positive for at least one of the antiphospholipid antibodies and 16% displayed more than one antibody in their serum. The mean values of anti CL IgG and anti β 2 GP I IgM were significantly higher in the patients (mean 11.32 ± 6.3 GPL and 4.43 ± 2.8 U/ml, respectively) as compared to the control group (mean 5.25 ± 1.9 and 1.6 ± 0.6, respectively) (P < 0.001). The concentrations of the tested antibodies were comparable among patients with focal compared to those with generalized seizure, or in patients with idiopathic compared to cryptogenic epilepsy. Patients with newly diagnosed untreated epileptic seizures showed a substantial prevalence of antiphospholipid antibodies. They even demonstrated significantly higher mean values of aβ2GP I IgG (10.7 ± 11 GPL) and aβ2GP I IgM (5.8 ± 3.0 U/ml) when compared to the rest of the patients (mean 5.9 ± 3.5 and 3.9 ± 2.6 respectively).There seem to be no effect of the different antiepileptic drugs or the degree of seizure control on the development of antiphospholipid antibodies. Conclusions: The antiphospholipid antibodies seem to be present at a higher rate in pediatric patients with epilepsy. The increased prevalence of those autoantibodies is associated with epilepsy regardless of the type of seizures, the antiepileptic drugs used or the degree of seizure control, suggesting that immune dysregulation may be linked to the pathogenesis of primary epilepsy. Keywords: anti β2 glycoprotein ; anticardiolipin; antiphospholipid; epilepsy; immune system Egypt J Pediatr Allergy Immunol 2004; 2(1): 58-65","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Antiphospholipid antibodies in children and adolescents with epilepsy\",\"authors\":\"O. El-Rasheidy, Shahira F El-Fedawy, H. Tomoum, Mona B El-Zeany\",\"doi\":\"10.4314/EJPAI.V2I1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Some immunologic mechanisms of epilepsy are cited in literature. The possibility that epilepsy might be associated with the production of autoantibodies has not been sufficiently addressed. Objective: This study investigates the prevalence of some antiphospholipid antibodies in pediatric primary epilepsy in relation to the type of seizures, the duration of the disease and the antiepileptic drugs received. Methods: The study included 37 patients in the pediatric age groups with epilepsy (30 with idiopathic epilepsy and 7 with cryptogenic epilepsy); 10 of them were newly diagnosed in comparison to ten healthy children. The patients were subjected to clinical, laboratory and radiologic evaluation to verify the diagnosis and to exclude thrombotic or autoimmune collagen disorders. Anticardiolipin IgG and IgM and anti-β 2 -glycoprotein I IgG and IgM antibodies were measured in all subjects using the ELISA technique. Results: Forty percent of the patients were positive for at least one of the antiphospholipid antibodies and 16% displayed more than one antibody in their serum. The mean values of anti CL IgG and anti β 2 GP I IgM were significantly higher in the patients (mean 11.32 ± 6.3 GPL and 4.43 ± 2.8 U/ml, respectively) as compared to the control group (mean 5.25 ± 1.9 and 1.6 ± 0.6, respectively) (P < 0.001). The concentrations of the tested antibodies were comparable among patients with focal compared to those with generalized seizure, or in patients with idiopathic compared to cryptogenic epilepsy. Patients with newly diagnosed untreated epileptic seizures showed a substantial prevalence of antiphospholipid antibodies. They even demonstrated significantly higher mean values of aβ2GP I IgG (10.7 ± 11 GPL) and aβ2GP I IgM (5.8 ± 3.0 U/ml) when compared to the rest of the patients (mean 5.9 ± 3.5 and 3.9 ± 2.6 respectively).There seem to be no effect of the different antiepileptic drugs or the degree of seizure control on the development of antiphospholipid antibodies. Conclusions: The antiphospholipid antibodies seem to be present at a higher rate in pediatric patients with epilepsy. The increased prevalence of those autoantibodies is associated with epilepsy regardless of the type of seizures, the antiepileptic drugs used or the degree of seizure control, suggesting that immune dysregulation may be linked to the pathogenesis of primary epilepsy. Keywords: anti β2 glycoprotein ; anticardiolipin; antiphospholipid; epilepsy; immune system Egypt J Pediatr Allergy Immunol 2004; 2(1): 58-65\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2004-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4314/EJPAI.V2I1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/EJPAI.V2I1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
摘要
背景:文献中引用了一些癫痫的免疫机制。癫痫可能与自身抗体的产生有关的可能性尚未得到充分的解决。目的:探讨小儿原发性癫痫中部分抗磷脂抗体的流行与癫痫发作类型、病程及抗癫痫药物的关系。方法:纳入37例小儿癫痫患者(特发性癫痫30例,隐源性癫痫7例);与10名健康儿童相比,其中10名是新诊断的。患者接受临床、实验室和放射学评估以验证诊断并排除血栓性或自身免疫性胶原蛋白紊乱。采用ELISA技术检测所有受试者的抗心磷脂IgG、IgM抗体和抗β 2 -糖蛋白I IgG、IgM抗体。结果:40%的患者血清中至少有一种抗磷脂抗体呈阳性,16%的患者血清中有不止一种抗体。患者抗CL IgG和抗β 2 GP I IgM的平均值(分别为11.32±6.3 GPL和4.43±2.8 U/ml)明显高于对照组(分别为5.25±1.9和1.6±0.6)(P < 0.001)。检测的抗体浓度在局灶性癫痫患者与全身性癫痫患者之间具有可比性,在特发性癫痫患者与隐源性癫痫患者之间具有可比性。新诊断的未经治疗的癫痫发作患者显示抗磷脂抗体的大量流行。他们的a - β 2gp I IgG(10.7±11 GPL)和a - β 2gp I IgM(5.8±3.0 U/ml)的平均值明显高于其他患者(平均分别为5.9±3.5和3.9±2.6)。不同的抗癫痫药物或癫痫发作控制程度对抗磷脂抗体的产生似乎没有影响。结论:抗磷脂抗体似乎在儿童癫痫患者中有较高的发生率。无论癫痫发作类型、使用的抗癫痫药物或癫痫发作控制程度如何,这些自身抗体的患病率增加都与癫痫有关,这表明免疫失调可能与原发性癫痫的发病机制有关。关键词:抗β2糖蛋白;anticardiolipin;antiphospholipid;癫痫;中华儿科杂志(英文版);2004;2 (1): 58 - 65
Antiphospholipid antibodies in children and adolescents with epilepsy
Background: Some immunologic mechanisms of epilepsy are cited in literature. The possibility that epilepsy might be associated with the production of autoantibodies has not been sufficiently addressed. Objective: This study investigates the prevalence of some antiphospholipid antibodies in pediatric primary epilepsy in relation to the type of seizures, the duration of the disease and the antiepileptic drugs received. Methods: The study included 37 patients in the pediatric age groups with epilepsy (30 with idiopathic epilepsy and 7 with cryptogenic epilepsy); 10 of them were newly diagnosed in comparison to ten healthy children. The patients were subjected to clinical, laboratory and radiologic evaluation to verify the diagnosis and to exclude thrombotic or autoimmune collagen disorders. Anticardiolipin IgG and IgM and anti-β 2 -glycoprotein I IgG and IgM antibodies were measured in all subjects using the ELISA technique. Results: Forty percent of the patients were positive for at least one of the antiphospholipid antibodies and 16% displayed more than one antibody in their serum. The mean values of anti CL IgG and anti β 2 GP I IgM were significantly higher in the patients (mean 11.32 ± 6.3 GPL and 4.43 ± 2.8 U/ml, respectively) as compared to the control group (mean 5.25 ± 1.9 and 1.6 ± 0.6, respectively) (P < 0.001). The concentrations of the tested antibodies were comparable among patients with focal compared to those with generalized seizure, or in patients with idiopathic compared to cryptogenic epilepsy. Patients with newly diagnosed untreated epileptic seizures showed a substantial prevalence of antiphospholipid antibodies. They even demonstrated significantly higher mean values of aβ2GP I IgG (10.7 ± 11 GPL) and aβ2GP I IgM (5.8 ± 3.0 U/ml) when compared to the rest of the patients (mean 5.9 ± 3.5 and 3.9 ± 2.6 respectively).There seem to be no effect of the different antiepileptic drugs or the degree of seizure control on the development of antiphospholipid antibodies. Conclusions: The antiphospholipid antibodies seem to be present at a higher rate in pediatric patients with epilepsy. The increased prevalence of those autoantibodies is associated with epilepsy regardless of the type of seizures, the antiepileptic drugs used or the degree of seizure control, suggesting that immune dysregulation may be linked to the pathogenesis of primary epilepsy. Keywords: anti β2 glycoprotein ; anticardiolipin; antiphospholipid; epilepsy; immune system Egypt J Pediatr Allergy Immunol 2004; 2(1): 58-65